Irritable bowel syndrome: toward an understanding of severity.
about
Aspects of the non-pharmacological treatment of irritable bowel syndromeCharacterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.Irritable bowel syndrome: more than abdominal pain and bowel habit abnormalities.Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.IBS and the role of otilonium bromide.Predictors of patient-assessed illness severity in irritable bowel syndrome.The use of data-mining to identify indicators of health-related quality of life in patients with irritable bowel syndrome.Latent structure of irritable bowel syndrome symptom severity.Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrheaTranslation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J)Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.The narcotic bowel syndrome: clinical features, pathophysiology, and managementA 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationRandomised controlled trial of mesalazine in IBS.Gender differences in gastrointestinal, psychological, and somatic symptoms in irritable bowel syndrome.Functional gastrointestinal disorders as a public health problem.The trials and tribulations of drug development for functional gastrointestinal disorders.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit.Adequate relief in a treatment trial with IBS patients: a prospective assessment.Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scalePsychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report.Chronic prenatal stress epigenetically modifies spinal cord BDNF expression to induce sex-specific visceral hypersensitivity in offspring.Severity in irritable bowel syndrome: a Rome Foundation Working Team report.Inaccuracy of patient-reported descriptions of and satisfaction with bowel actions in irritable bowel syndrome.A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria.Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID.Design and validation of a German version of the GSRS-IBS - an analysis of its psychometric quality and factorial structure.Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders.Mechanisms of protease-activated receptor 2-evoked hyperexcitability of nociceptive neurons innervating the mouse colon.Measurement of oro-caecal transit time by magnetic resonance imaging.Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: Results from patient and healthcare professional surveys
P2860
Q26777536-DC653AA9-7D07-4370-B1EE-92ECF99C69C4Q30433548-B79E3067-8335-41FC-A2AE-7832649629B2Q33441714-DA4A9CFE-F62C-442B-A65C-AAE7C8F73F0BQ33456102-1ED1702F-E9FC-491B-8164-F251E008E0F5Q33456428-96C3A5FD-F016-4E8F-8002-70FF5CBCA574Q34170665-279334E6-1B03-449C-A84B-24F592145EDDQ34416849-963E771E-C112-46F6-98FE-257E1E56EAD3Q34827497-31372943-D95C-4D9C-9ACC-FF0645513439Q35552818-B86079B5-A028-4531-A2C4-B8D24D656714Q35699652-CC4CA9DA-833D-4FD3-ABC1-62B1C26F2FA4Q35843069-D09DD328-9346-4F24-BD92-3D17D27DA4C0Q36136622-38EA62A3-48FE-47C0-AF6E-06F3E68C07C6Q36417684-5CF3C149-C50C-4D0D-9D0D-C63BD74F188FQ36475502-08ACBD2A-A4EB-4FFB-B338-3C3C99189459Q36601630-B80E4AFA-9F44-4DF2-ABCE-D178835294EBQ37134568-31EA4671-BCA9-4B0E-98ED-D5F1AC6F3B1BQ37134572-09FA726C-37DB-4F02-B233-158B110CADBEQ37164063-9C54113F-31D4-4E84-BD47-C2DC02F00CCFQ37237195-67C478A6-0FB1-48F0-A06E-A2E841AAD485Q37253528-145886EC-9C6C-45D8-A5C3-399BA5493391Q37475265-6B6F2CA2-B57A-469A-ACC7-D67B3570C685Q37475280-94442D7A-4636-4AFB-BAA1-A45C39E6A7FFQ37719767-58FC094D-FD2E-4E4D-A16B-DA1D809A8A00Q37900126-F26AB6B2-17B0-463F-B3B3-6327819915AFQ38629237-892C259F-5E08-4414-9EE9-A53E96F38FB9Q39335358-9AC54E9F-D0E8-4EEB-89BA-011B0F75D22FQ43171523-D6D52B05-A4D5-457E-89EC-FA3213119D33Q43327979-7183A44B-1478-412E-9816-742407C32880Q46972620-13A98F9A-549D-4F31-8CAF-41C2E7A018C0Q47117663-A9670BFB-CC04-4F70-900C-CB865F7BC053Q48591980-382C45E8-44F9-4C68-AD55-3EDFD164858EQ48622632-ECB6EE8A-D5DA-4FF2-83D5-DE08DDCF8D6FQ51667996-01328BBE-7CD5-40E7-8508-0546D59E86BDQ58579625-70823F54-D021-4D02-95F3-91C084554A82
P2860
Irritable bowel syndrome: toward an understanding of severity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Irritable bowel syndrome: toward an understanding of severity.
@ast
Irritable bowel syndrome: toward an understanding of severity.
@en
type
label
Irritable bowel syndrome: toward an understanding of severity.
@ast
Irritable bowel syndrome: toward an understanding of severity.
@en
prefLabel
Irritable bowel syndrome: toward an understanding of severity.
@ast
Irritable bowel syndrome: toward an understanding of severity.
@en
P2093
P1476
Irritable bowel syndrome: toward an understanding of severity.
@en
P2093
Anthony Lembo
Douglas A Drossman
Vanessa Z Ameen
P304
P356
10.1016/S1542-3565(05)00157-6
P407
P577
2005-08-01T00:00:00Z